Liu et al. [53] examined the impact of co-administering HDG and cisplatin on Ncl-H6 lung cancer in mice and demonstrated that HDG enhances the responsiveness of cancer cells to cisplatin, resulting in increased caspase-3 and PARP levels as well as increased ROS levels in lung cancer cells. This evidence concerns the gene CASP3 and lung carcinoma.